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Summary. The potential relevance of murine athero-
thrombosis models for understanding human disease has
been debated in the past. Despite this, in the last decade,
many thrombosis studies with atherogenic Apoe/ mice
have been performed, which provide novel insight into
the molecular mechanisms by which platelet and coagula-
tion processes accomplish acute thrombus formation after
plaque disruption in vivo. Support for these mechanisms
has come from whole blood flow perfusion studies over
plaque material in vitro, which are also reviewed in this
study. The main plaque-derived triggers for thrombus for-
mation appear to be collagen and tissue factor, next to
bioactive mediators such as prostaglandin E2. The ath-
erothrombotic process relies on collagen- and ADP-recep-
tor-induced platelet activation as well as on thrombin/
fibrin generation via the extrinsic and intrinsic coagula-
tion pathways. Less is known of the persistent effects of a
thrombus on atherosclerosis progression, but evidence
suggests roles herein of activated platelets and ongoing
thrombin generation.
Keywords: atherosclerotic plaque; blood coagulation;
mouse; platelets; rupture; thrombosis.
Introduction
Atherothrombosis, characterized by the acute formation
of a thrombus following rupture or erosion of an athero-
sclerotic plaque, is a major cause of acute coronary syn-
drome and cardiovascular death. Atherothrombosis is
considered to be triggered by a dysfunctional or damaged
endothelium causing exposure of subendothelial plaque
tissue to the blood stream. This leads to a series of
thrombogenic responses, potentially resulting in occlusion
of the atherosclerotic artery by a formed thrombus. The
reactions leading to thrombus formation after injury of a
healthy, non-atherosclerotic artery have been schematised
in several reviews, with as main processes platelet activa-
tion, thrombin generation, and fibrin clot formation [1,2].
Commonly used schemes start with platelet adhesion to
von Willebrand factor (VWF), which is facilitated by the
high shear rate at the arterial vessel wall. Subsequent
aggregation of platelets is promoted by the release of
paracrine mediators, for example, ADP and thromboxane
[2]. Thrombin, generated at the surface of a subpopula-
tion of procoagulant platelets and at disrupted (sub)endo-
thelial membranes, activates platelets and cleaves
fibrinogen into fibrin. In this way, thrombin promotes
thrombus growth, thrombus stabilization, and the massive
fibrin-dependent entrapment of red blood cells at down-
stream sites of lower shear rate [1,3]. This concept of
thrombus formation is in agreement with the histology of
many thrombotic coronary and carotid arteries obtained
from patients during surgery or autopsy, in which
thrombi with a white platelet-containing head and a large
red tail enriched in fibrin and erythrocytes are demon-
strated [4]. It should be taken into account that these
schemes are largely based on in vitro flow perfusion stud-
ies and in vivo animal (predominantly mouse) studies
where the thrombotic process is investigated in non-ath-
erosclerotic arteries.
Besides the acute process of thrombus formation, there
is substantial evidence for a more persistent activity of
platelets and coagulation in atherosclerosis and thrombo-
sis. Autopsy material from patients with unstable angina
or acute myocardial infarction frequently shows multilay-
ered plaques containing intraplaque fibrin patches, sug-
gestive for repeated episodes of (clinically silent)
thrombotic activities followed by lesion growth [4]. Fur-
thermore, arterial thrombi obtained by aspiration from
patients with acute myocardial infarction show evidence
for prolonged thrombotic activity prior to the thrombotic
event [5]. Together, this is suggestive for subacute and
likely continuous activity of platelets and coagulation in
an atherosclerotic vessel that is prone to thrombogenesis.
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In support of this concept, in many studies, the beneficial
effect of prolonged antiplatelet treatment for secondary
prevention of atherothrombosis has been demonstrated.
However, the currently used antiplatelet agents, blocking
cyclooxygenase (aspirin) or P2Y12 receptors (clopidogrel,
prasugrel), do not completely annul the risk of new
thrombotic events [6].
Here, we aim to provide an overview of in vivo
thrombosis studies using atherogenic Apoe/ mice and
of in vitro perfusion studies using isolated plaque mate-
rial, on the mechanisms by which platelet and coagula-
tion processes contribute to acute thrombus formation
on a disrupted plaque. We also propose mechanisms by
which persistent activities of the hemostatic system, that
is, after the formation of a thrombus, can aggravate
atherosclerosis.
Changing paradigms on animal models of plaque
rupture and atherothrombosis
In 2003, a consensus paper identified a number of restric-
tions for the use of animal models in the study of athero-
thrombosis after plaque rupture [7]. Major limitations
were seen in the observations that: (i) particularly in
mouse and rabbit models, the atherosclerotic lesions are
histologically different from the plaques in man in terms
of fibrous cap and lipid core; (ii) the size of animal lesions
is considerably smaller than in man; (iii) the vulnerability
to rupture of animal plaques is quite low when compared
to human plaques; and (iv) plaque rupture in animals
does only rarely occur without vigorous manipulations,
for example, without using a needle or laser. It was stipu-
lated that, for an ideal animal model of plaque rupture,
thrombi should be formed via the same mechanisms and
be sensitive to the same drug treatments as the thrombi
formed in cardiovascular patients.
In spite of this rather negative outlook, in the last dec-
ade, a considerable number of animal studies have been
published on thrombus formation induced by atheroscle-
rotic plaque disruption, mostly using mice or rabbits.
Together, this work provides unexpected new insights into
the mechanisms of ‘animal’ atherothrombosis with clear
relevance for the human situation. Most of the mechanis-
tic studies have been carried out in Apoe/ mice, which
are prone to atherosclerosis when fed high-fat diets.
Therefore, in this review, we concentrate on published
experimental atherothrombosis in vivo studies using
Apoe/ mice as well as on in vitro whole blood perfusion
studies using isolated plaque material.
Novel mouse models of atherothrombosis
In a hallmark paper, Reddick et al. [8] described for the
first time the formation of a thrombus on a damaged
mouse plaque, provoked by clamping the murine athero-
sclerotic aorta. Since then, a wide range of in vivo murine
models of atherothrombosis have been developed and
exploited predominantly with Apoe/ mice. Damage of
the atherosclerotic vessel wall has been triggered by dif-
ferent approaches, that is, from inside the vessel (needle
insertion, photochemical, or pharmacological interven-
tion) or from the outside (clamping, ligation, injury by
laser light, ultrasound power, or FeCl3 application). The
process of thrombus formation is quantified in many
papers (Table 1). However, the extent of plaque disrup-
tion has in only few occasions been verified by histologi-
cal analysis and appeared to vary with the methodology
applied [9,10]. The formation of either non-occlusive or
occlusive thrombi is described, putatively depending on
the size and severity of the vascular (plaque) damage or
disruption. For instance, the local plaque rupture induced
by targeted ultrasound application resulted in non-occlu-
sive thrombus formation [9], whereas the more broad
application of FeCl3 or illumination of a photosensitive
dye led to full arterial occlusion [11–13]. It should be
noted that the latter two techniques primarily cause denu-
dation or disturbance of the endothelium rather than pla-
que disruption, as seen with ultrasound or inside wire
treatment. For a more extensive description of the pros
and cons of the various injury models, we like to refer to
other reviews [14,15]. Here, we aim to discuss in an inte-
grative way the mechanisms by which thrombi are formed
in an atherosclerotic vessel irrespective of the trigger. For
the present purpose, we consider all thrombus formation
in mouse atherosclerotic arteries as experimental athero-
thrombosis.
In addition to these in vivo models, flow chambers with
atherosclerotic plaques have also been used for in vitro
studies of athero-induced thrombus formation. The first
generation flow devices in the seventies and eighties made
use of isolated atherosclerotic vessel wall segments that
were everted around a central rod [16]. In the last decade,
mostly transparent parallel-plate flow chambers have been
employed, coated with homogenized atherosclerotic pla-
que material, and perfused with blood under controlled
flow conditions. Advantages of the latter devices are that
they require only small blood volumes and that the
thrombotic process can be imaged in real time [16].
Table 2 summarizes relevant studies investigating throm-
bus formation on plaque material using mouse, pig, or
human blood.
Plaque-derived collagens and platelet collagen receptors
in atherothrombosis
Although the fibrillar type I and III collagens are known
to stabilize an atherosclerotic plaque, there is considerable
evidence that these collagens become platelet-activating
upon exposure to the blood stream. Similar to thrombus
formation in non-atherosclerotic arteries [17], the platelet
collagen receptor, glycoprotein VI (GPVI) has been found
to play a key role in thrombus formation on exposed
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plaque collagens. Accordingly, blockage of GPVI with a
monoclonal antibody abolished the thrombotic process in
Apoe/ mice in vivo triggered by ultrasound-induced
plaque rupture (Table 1) [9,10]. Interestingly, athero-
thrombosis induced by needle insertion appeared to be less
sensitive to GPVI blockage than the ultrasound model,
whereas the thrombotic process in both models was sup-
pressed by thrombin inhibition [10]. In vitro, blockage
of GPVI abrogated plaque-induced human thrombus for-
mation in a flow chamber (Table 2) [18–20]. In such a
flow chamber system, no role of the other platelet colla-
gen receptor, integrin a2b1, could be demonstrated [19].
Consistent with a platelet-activating role for type I and III
collagens in atherothrombosis is the observation that, in
serial cross sections of human atherosclerotic plaques,
the areas of high platelet deposition are enriched in these
collagens [21].
Roles of other platelet signaling proteins in
atherothrombosis
Given the key platelet-activating role of GPVI in experi-
mental atherothrombosis, one can assume that also other
platelet signaling proteins with known involvement in















Thrombus ↓, emboli ↑ Neointima = [9,10,23,24]
CD40 Cd40/ CA: ultrasound Thrombus ↓ [9]
Cyclooxygenase 1 Aspirin CA: ligation Thrombus = Neointima = [24]
Dense granules Hps3/ CA: FeCl3 Occlusion time ↑ LC infiltration ↓,
neointima ↓*
[12]
Glycoprotein VI JAQ1 Ab CA: inside needle,
ultrasound
Thrombus ↓ [9,10]
Integrin aIIbb3 Eptifibatide CA: inside needle,
ultrasound
Thrombus ↓ [10]
PGE2 receptor EP3 Ptger3
/, DG-041 CA: inside needle Thrombus ↓ [26,27]
PI 3-kinase b TGX-221 CA: ultrasound Thrombus ↓ [9]
Plasma components





FII+FX EP217609 CA: inside needle Thrombus ↓ [38]
FVII FVIIa inhibitor CA: photochemical,
ultrasound
Thrombus ↓, emboli =,
occlusion time ↑,
[13,31]
FX Fondaparinux CA: inside needle Thrombus ↓ [38]
FXI Antisense, anti-FXI Ab CA: ultrasound,
photochemical
Thrombus ↓, emboli ↑,
occlusion time =
LC infiltration ↑* [13,34]
FXII CTI, rHA-Infestin-4 CA: ultrasound,
photochemical
Thrombus ↓, emboli ↑ [13,31]
Interferon-a IFNa adenovirus CA: photochemical Occlusion time ↓ Neointima = [59]





TFPI Tfpi+/ CA: photochemical Occlusion time ↓ Neointima ↑ [32]
Tissue factor Anti-TF Ab CA: photochemical Occlusion time ↑ [13]
Vascular components
CCL2 (JE/MCP-1) Ccr2/, 2H5 Ab CA: inside wire LC adhesion↓,
neointima ↓*
[50]
Fibrilin-1 Fbn1C1039G+/ AO: spontaneous Thrombus ↑ Neointima ↑ [45]
Lipoprotein lipase Lpl/ CA: FeCl3 Thrombus ↑ Neointima ↑* [43]
Leptin receptors Leptin CA: photochemical Occlusion time ↓ Neointima ↑ [44]
MMP-9 Active MMP-9
expression in MΦ
AO: spontaneous Thrombus ↑ [46]
Niemann-Pick C1 Npc1/ AO: spontaneous Thrombus ↑ Neointima ↑ [48]
p53 p53 overexpression
in SMC
AO: spontaneous Thrombus ↑ Neointima =, cap/
intima ratio ↓
[47]
Thrombomodulin TMPro/Pro CA: FeCl3 Occlusion time ↓ Neointima ↑ [55]
Only studies providing quantitative data are cited. Ab, antibody; CA, carotid artery; AO, aorta; LC, leukocyte; = unchanged; ↑ increased; ↓
decreased.
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collagen-dependent thrombus formation [1,2] can contrib-
ute to the assembly of thrombi on a damaged atheroscle-
rotic plaque. This has been demonstrated for the GPIb-
V-IX complex, interacting with collagen-bound VWF,
which was mediated initial platelet adhesion to plaque
material at high, but not at low wall-shear rates [22].
Another contributor is the platelet ADP receptor P2Y12,
which was found to act by stabilizing thrombi formed on
disrupted plaques of Apoe/ mice in vivo as well as in flow
devices in vitro [23] (Fig. 1). In contrast, the other platelet
ADP receptor, P2Y1, does not seem to have a major role
in thrombus formation [18,22]. Finally, atherothrombus
formation in vivo was inhibited by blocking phosphoinosi-
tide 3-kinase b or integrin aIIbb3 [9,10], which are impli-
cated in platelet aggregation. In vitro and in vivo studies
indicated that blockage of thromboxane formation with
aspirin did not impair thrombus formation on atheroscle-
rotic plaques [22,24]. The latter findings are in line with
data from in vitro perfusion studies over purified collagen
in which either no effect or reduced thrombus formation
was observed after aspirin addition or treatment [16]. An
interesting observation in this regard is that aspirin treat-
ment of patients with peripheral artery disease, in whom
platelet reactivity is generally increased, was found to nor-
malize thrombus formation under flow [25]. This suggests
that the net effect of aspirin on thrombus formation is
influenced by the basal platelet activation state.
Some controversy exists on a role of the platelet EP3
receptor for prostaglandin E2 in atherothrombosis mod-
els. This prostaglandin can be produced in murine and
human atherosclerotic plaques, and reports exist that
blockage or absence of the EP3 receptor reduces throm-
bus formation in Apoe/ mice [26,27]. However, another
report describes no effect of EP3 receptor blockers on
plaque-induced human thrombus formation in vitro [28].
A possible explanation for the latter observation is that
plaque-derived prostaglandin E2 is reported to be only
shortly active after plaque dissection [27]. Yet, additional
research is needed to resolve this matter.
The extrinsic coagulation pathway in acute
atherothrombosis
In the atherosclerotic vessel wall, several cell types express
tissue factor (TF), especially macrophages and smooth
muscle cells. Upon exposure to the blood stream, de-
encrypted TF forms a complex with coagulation factor
FVII(a), which activates FIX, FX, and prothrombin, in
proteolytic reactions that are potently stimulated by the
tenase and prothrombinase complexes [2]. These com-
plexes are efficiently formed on phosphatidylserine-expos-
ing, procoagulant membranes, including GPVI-stimulated
platelets, injured vascular cells, and microparticles [2]. In
vitro flow chamber and thrombin generation studies point
Table 2 Literature evidence for involvement of platelet and plasma components in atherothrombus formation in flow perfusion studies in vitro






ADP receptor P2Y1 H MRS-2179 PP: carotid plaque (H) Thrombus ↓ [18,22]
ADP receptor P2Y12 H Cangrelor, ticagrelor PP: carotid plaque (H) Thrombus ↓,
emboli ↑
[18,22,23]
ADP receptor P2Y12 M P2ry12
/ PP: aortic plaque (M) Thrombus ↓,
emboli ↑
[23]
Cyclooxygenase-1 H Aspirin PP: carotid plaque (H) Thrombus = [22]
Glycoprotein Ib-V-IX H 6B4 Ab PP: carotid plaque (H) Thrombus ↓ [22]
Glycoprotein VI H GPVI-Fc protein;
10B12, 9O12 Ab
PP: carotid plaque (H) Thrombus ↓ [18–20]
Glycoprotein VI M JAQ1 Ab PP: carotid artery (H) Thrombus ↓ [19]
Integrin a2b1 H 6F1 Ab PP: carotid plaque (H) Thrombus = [19]
Integrin a2b1 M Itga2/ PP: carotid plaque (H) Thrombus = [19]
PGE2 receptor EP3 H AE5-599, AE3-240 PP: carotid plaque (H) Thrombus = [28]
Serotonin receptor 5HT2A H Ketanserin, R-96544 PP: arterial plaque (H) Thrombus = [60]
Plasma components
FVII H FVIIai PP: carotid plaque (H) Thrombus ↓ [31]
FVII M FVIIai PP: aortic plaque (M) Thrombus ↓ [31]
FXII H CTI, FXII-deficient patient PP: carotid plaque (H) Thrombus ↓/= [20,31]
FXI, FXII M F11/, F12/, F11//F12/ PP: aortic plaque (M) Thrombus ↓ [31]
Lipoproteins
(HDL ↑ LDL ↓)
P Gemfibrozil TB: carotid plaque (P) Thrombus = [61]
Tissue factor P Anti-TF Ab, TFPI TB: arterial plaque (H) Thrombus ↓/=,
emboli ↓
[20,30]
Platelet membranes H Microparticles TB: aortic plaque (H) Thrombus ↑,
emboli ↑
[62]
Only studies providing quantitative data are cited. H, human; M, mouse; P, pig; Ab, antibody; PP, parallel plate; TB, tubular; = unchanged; ↑
increased; ↓ decreased.
© 2015 International Society on Thrombosis and Haemostasis
Platelets and coagulation in atherothrombosis S275
to a high thrombogenicity of the TF-enriched, inner ath-
eromatous plaque core [29]. Using Apoe/ mice, sub-
jected to ultrasound plaque rupture or photochemical
injury, it was shown that inhibition of the TF/FVIIa com-
plex diminishes the process of thrombus formation, point-
ing to a key role of the extrinsic coagulation pathway in
experimental atherothrombosis [9,13]. A role of TF has
also been observed in vitro in flow perfusion studies using
human plaque material [20,30,31]. In this case, inhibition
of TF did not affect platelet aggregation, but markedly
delayed fibrin formation [20]. In line with these data, het-
erozygous deficiency in tissue factor pathway inhibitor
(TFPI), the major TF antagonist, was found to stimulate
thrombus formation in Apoe/ mice [32].
Roles of the intrinsic coagulation pathway
The intrinsic coagulation pathway, which according to its
name can operate with blood factors only, is triggered by
contact of FXII with negatively charged surfaces, through
its cleavage by high molecular weight kininogen and kal-
likrein. It has been shown that fibrillar collagens such as
present in plaques can bind FXII and support the activa-
tion to FXIIa [33]. Like thrombin, activated FXII cleaves
FXI, which in turn cleaves FIX. Several observations
point to a unique role of this pathway in experimental
atherothrombosis (Fig. 1). In an in vivo model of ultra-
sound-induced plaque rupture, inhibition of FXIIa or
treatment with FXI antisense oligonucleotides caused a
substantial suppression of thrombus formation [31,34].
This corresponds well to findings with damaged healthy
(non-atherosclerotic) arteries, where thrombus formation
was markedly impaired and destabilized in mice lacking
FXII or FXI [35,36]. On the other hand, in an athero-
thrombosis model of FeCl3 application, no prominent
role of FXII could be observed [13]. In in vitro studies
where blood was flowed over plaque material, inhibition
of FXIIa with corn trypsin inhibitor (human) or the
absence of FXII or FXI (mouse) led to unstable throm-
bus formation [31]. Interestingly, immunostaining indi-
cated that some FXIIa was located at collagen fibers in
the plaque, but that the bulk of FXIIa co-localized with
fibrin fibers. As the majority of this work points to a
clear role of the FXII pathway in atherothrombus forma-
tion without affecting hemostasis, the intrinsic coagula-
tion pathway may be an attractive target for
antithrombotic drugs with low risk of bleeding. Evidence
for this comes from a recent study, in which a lowered
FXI level by antisense oligonucleotide treatment was
shown to reduce the occurrence of postoperative venous
thromboembolism in patients undergoing elective primary
unilateral total knee arthroplasty [37].
Thrombus embolization
Clinical studies indicate that embolization is a frequent
phenomenon during and after arterial thrombosis, espe-
cially in the carotid arteries, although it often remains
clinically silent. At present, embolization has only limit-




































Fig. 1. Schematic overview of factors involved in thrombus formation at a site of plaque disruption. A ruptured or eroded atherosclerotic pla-
que rapidly recruits circulating platelets, which interact with thrombogenic substances such as collagen and PGE2 of the plaque interior. Colla-
gen also binds and activates FXII, which results in sequential activation of FXI and FIX, and subsequent thrombin generation. Thrombin is
also generated via plaque-derived tissue factor in complex with FVIIa. Thrombin activates platelets and cleaves fibrinogen into fibrin, which
acts in thrombus stabilization and accomplishes massive trapping of red blood cells. Activated platelets secrete secondary mediators ADP and
TxA2 to recruit other platelets and form a stable platelet aggregate. Furthermore, they release growth factors and cytokines, which in interplay
with coagulant (thrombin), anticoagulant (thrombomodulin), and antifibrinolytic (PAI-1, TFPI) factors exert persistent vessel wall directed
activities.
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models. The few reports on thrombus stability point to
increased embolus formation upon blockage of the plate-
let P2Y12 receptors or the coagulation factors FXI or
FXII in Apoe/ mice [10,13,38]. Similar embolizing
effects by P2Y12 or FXII blockage have been described
for thrombi that are formed on injured, non-atheroscle-
rotic arteries [39]. This supports the idea that the stability
of thrombi is similarly regulated after disruption of an
atherosclerotic or a healthy artery.
Role for PAI-1 in atherothrombus dissolution
In a few thrombosis studies, a role of the fibrinolytic
pathway has been investigated, with primary focus on
involvement of the fibrinolysis suppressor, plasminogen
activator inhibitor-1 (PAI-1). In PAI-1-deficient mice, ath-
erothrombus formation was shown to be repressed, while
the time to vascular occlusion was increased [40–42].
Other support for a role of PAI-1 is the finding that the
increased thrombus formation in Apoe/ mice caused a
high-fat diet is accompanied by a higher arterial expres-
sion of PAI-1 [40,42,43]. Although much is known of the
dynamics of the thrombus-forming process [1–3,39], our
insight into the mechanisms of thrombus dissolution is
still limited.
Roles of vascular proteins in acute atherothrombosis
There is evidence for a role of vascular proteins other
than TF and collagen in atherothrombus formation. In
Apoe/ mice, it has been reported that lipoprotein lipase
and leptin receptors in the vessel wall have a suppressive
effect on atherothrombus formation, via mechanisms that
are unknown [43,44]. Also unexplored is how vessel wall
proteins facilitate ‘spontaneous’ or induced thrombosis in
different atherosclerotic vascular beds of Apoe/ mice.
So far, unprovoked thrombus formation has been exam-
ined in mice with: (i) mutations in elastin-fragmenting fi-
brilin-1 [45]; (ii) overexpression of activated matrix-
degrading matrix metalloproteinase-9 in the plaque mac-
rophages [46]; (iii) overexpression of the tumor suppressor
gene p53 in smooth muscle cells when triggering with
phenylephrine [47]; and (iv) deficiency in the Niemann-
Pick C1 protein, although it should be remarked here that
Npc1-deficient mice display shortened coagulation times
in plasma [48]. Congruous for these cases of spontaneous
plaque disruption and thrombosis are intraplaque hemor-
rhages, increased fibrin deposition, increased matrix deg-
radation, and increased neointima formation, which are
jointly indicative for a vulnerable plaque phenotype [4].
Persistent platelet activities in atherothrombosis
Atherosclerosis and atherothrombosis have aptly been
described as an ‘insidious cycle of acute inflammation and
thrombosis,’ often remaining clinically silent until the
development of a catastrophic cardiovascular event [1].
Indeed, in Apoe/ mice, persistent interactions of plate-
lets with the atherosclerotic vessel wall have been
observed, which may contribute to the progression of pla-
que formation [49]. Smooth muscle cells may promote pla-
que formation by the release of CC chemokine ligand 2
(CCL2), which binds to the platelet CCR2 receptors and
facilitates platelet–monocyte interaction. The CCL2–
CCR2 axis appears to promote neointima formation, also
after inside wire-induced atherothrombosis [50]. Platelets
themselves contain large pools of bioactive proteins,
including many growth factors and cytokines, in their
storage granules [51]. These platelet-derived biomediators,
released at the inflamed or damaged vessel wall, are likely
to play a role in the propagation of atherosclerosis [49,52].
Support for this concept comes from experimental athero-
thrombosis studies with Apoe//Hps3/ mice, which
lack platelet-dense granules. After provoked thrombosis,
deficiency in HPS3 led to a reduction in platelet–leukocyte
aggregates and to a diminished neointima formation [12].
Considering that ADP is a main constituent of the
dense granules and that platelet-derived ADP greatly sup-
ports thrombus formation, it may be expected that ADP
also contributes to atheroprogression. However, in
Apoe/ mice, blockage of the main ADP receptor P2Y12
or blockage of thromboxane formation with aspirin was
without effect on platelet–vessel wall interaction or neoin-
tima formation [24]. Along the same line, two studies
indicate that neither clopidogrel nor aspirin affects vascu-
lar stiffness in patients with coronary artery disease
[53,54]. This suggests that, although clopidogrel and aspi-
rin effectively antagonise incorporation of new platelets
into a thrombus, the effects of these drugs on platelet
adhesion-dependent atheroprogression are limited. How-
ever, further research is required to definitively assess the
effect of these antiplatelet drugs on the suppression of
platelet activities once a thrombus is formed.
Persistent coagulant and fibrinolytic activities in
atherothrombosis
Impaired generation of thrombin, such as in mice with a
gene-targeted 50% reduction in prothrombin, attenuated
atherosclerotic progression [55]. Conversely, hypercoagula-
bility in mice with inactive thrombomodulin promoted ath-
erothrombosis as well as atherosclerosis progression [55].
Similarly, other studies indicate that thrombin inhibition
can have a long-term stabilizing effect on atherosclerotic pla-
ques [56]. Whether the fibrinolysis process is also active at
later stages is less clear. One paper suggests that, in the pres-
ence of a fibrin-containing thrombus, the fibrinolysis inhibi-
tor PAI-1 stimulates neointima formation [42]. Other studies
indicate that, in the absence of an overt thrombotic trigger,
deficiency in PAI-1 leads to either increased [41] or site-
specific decreased [40] neointima formation. A site-specific
effect has also been reported for TFPI, which may act to
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suppress atherosclerosis particularly at sites of turbulent
flow, that is, in the carotid bifurcation [32]. Together, this
suggests that the long-term vascular effects of hemostatic
factors on the vessel wall rely on the presence of an appro-
priate thrombotic trigger and specific biorheologic condi-
tions. Absence of a thrombus may also explain why a 50%
reduction of TF was without effect on the development of
murine atherosclerotic lesions [57].
Conclusions
In contrast to perhaps what was expected in 2003 [7],
recent work on mouse models of provoked thrombosis in
atherosclerotic arteries in vivo has provided considerable
insight into the molecular mechanisms underlying the
process of atherothrombosis. Further support for these
mechanisms comes from in vitro studies where mouse or
human whole blood is perfused over isolated atheroscle-
rotic plaque material. Current data indicate that the main
plaque-derived factors triggering acute thrombus forma-
tion are collagen and TF, next to bioactive mediators like
prostaglandin E2 produced by smooth muscle cells and
macrophages, which can to attract platelets. Jointly, these
studies indicate that the atherothrombotic process is regu-
lated by similar mechanisms as the process of thrombus
formation in damaged non-atherosclerotic vessels. Key
event herein are collagen- and ADP-receptor-dependent
platelet activation and thrombin/fibrin generation via the
extrinsic and intrinsic coagulation pathways. Less is
known of the persistent effects of a thrombus on neointi-
ma formation and atherosclerosis progression, but the
available evidence suggests a role herein of both activated
platelets and ongoing thrombin generation. The clinical
evidence of this is already becoming clear, because com-
bined inhibition of platelets (aspirin plus a thienopyri-
dine) and coagulation (FXa inhibitor rivaroxaban) can
lead to an additional decrease in in-stent thrombosis and
mortality in patients with acute myocardial infarction,
when compared to dual antiplatelet therapy alone [58].
Acknowledgements
We report grants from the Netherlands Heart Foundation
(2011T6) to J. M. E. M. Cosemans, and ZonMW
(MKMD 114021004), the Netherlands to J. M. W.
Heemskerk and J. M. E. M. Cosemans during the con-
duct of the study.
Disclosure Conflict of Interests
The authors state that they have no conflict of interest.
References
1 Jackson SP. Arterial thrombosis: insidious, unpredictable and
deadly. Nat Med 2011; 17: 1423–36.
2 Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New funda-
mentals in hemostasis. Physiol Rev 2013; 93: 327–58.
3 Heemskerk JW, Mattheij N, Cosemans JM. Platelet-based coag-
ulation: different populations, different functions. J Thromb Hae-
most 2013; 11: 2–11.
4 Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of pla-
que formation and rupture. Circ Res 2014; 114: 1852–66.
5 Rittersma SZ, van der Wal AC, Koch KT, Piek JJ, Henriques
JP, Mulder KJ, Ploegmakers JP, Meesterman M, de Winter RJ.
Plaque instability frequently occurs days or weeks before occlu-
sive coronary thrombosis: a pathological thrombectomy study in
primary percutaneous coronary intervention. Circulation 2005;
111: 1160–5.
6 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Bor-
den WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Ful-
lerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ,
Huffman MD, Kissela BM, Kittner SJ, Lackland DT, et al.
Heart disease and stroke statistics-2013 update: a report from
the American Heart Association. Circulation 2013; 127: e6–245.
7 Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella
A, von Eckardstein A, Exley A, Goddard M, Hofker M, Hurt-
Camejo E, Kanters E, Kovanen P, Lorkowski S, McPheat W,
Pentikainen M, Rauterberg J, Ritchie A, Staels B, Weitkamp B,
et al. Rupture of the atherosclerotic plaque: does a good animal
model exist? Arterioscler Thromb Vasc Biol 2003; 23: 535–42.
8 Reddick RL, Zhang SH, Maeda N. Aortic atherosclerotic plaque
injury in apolipoprotein E deficient mice. Atherosclerosis 1998;
140: 297–305.
9 Kuijpers MJ, Gilio K, Reitsma S, Nergiz- €Unal R, Prinzen L,
Heeneman S, Lutgens E, van Zandvoort MA, Nieswandt B, Eg-
brink MG, Heemskerk JW. Complementary roles of platelets
and coagulation in thrombus formation on plaques acutely rup-
tured by targeted ultrasound treatment: a novel intravital model.
J Thromb Haemost 2009; 7: 152–61.
10 Hechler B, Gachet C. Comparison of two murine models of
thrombosis induced by atherosclerotic plaque injury. Thromb
Haemost 2011; 105: S3–12.
11 Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Hyper-
lipidemia promotes thrombosis after injury to atherosclerotic ves-
sels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc
Biol 2000; 20: 1831–4.
12 King SM, McNamee RA, Houng AK, Patel R, Brands M, Reed
GL. Platelet dense-granule secretion plays a critical role in
thrombosis and subsequent vascular remodeling in atheroscle-
rotic mice. Circulation 2009; 120: 785–91.
13 Jiang P, Xue D, Zhang Y, Ye L, Liu Y, Makale M, Kesari S,
Edgington TS, Liu C. The extrinsic coagulation cascade and tis-
sue factor pathway inhibitor in macrophages: a potential thera-
peutic opportunity for atherosclerotic thrombosis. Thromb Res
2014; 133: 657–66.
14 Westrick RJ, Winn ME, Eitzman DT. Murine models of vascu-
lar thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol
2007; 27: 2079–93.
15 Kretz CA, Vaezzadeh N, Gross PL. Tissue factor and thrombo-
sis models. Arterioscler Thromb Vasc Biol 2010; 30: 900–8.
16 van Kruchten R, Cosemans JM, Heemskerk JW. Measurement
of whole blood thrombus formation using parallel-plate flow
chambers: a practical guide. Platelets 2012; 23: 229–42.
17 Nieswandt B, Pleines I, Bender M. Platelet adhesion and activa-
tion mechanisms in arterial thrombosis and ischaemic stroke. J
Thromb Haemost 2011; 9 (Suppl. 1): 92–104.
18 Cosemans JM, Kuijpers MJ, Lecut C, Loubele ST, Heeneman S,
Jandrot-Perrus M, Heemskerk JW. Contribution of platelet gly-
coprotein VI to the thrombogenic effect of collagens in fibrous
atherosclerotic lesions. Atherosclerosis 2005; 181: 19–27.
19 Penz S, Reininger AJ, Brandl R, Goyal P, Rabie T, Bernlochner
I, Rother E, Goetz C, Engelmann B, Smethurst PA, Ouwehand
© 2015 International Society on Thrombosis and Haemostasis
S278 T. G. Mastenbroek et al
WH, Farndale R, Nieswandt B, Siess W. Human atheromatous
plaques stimulate thrombus formation by activating platelet gly-
coprotein VI. FASEB J 2005; 19: 898–909.
20 Reininger AJ, Bernlochner I, Penz SM, Ravanat C, Smethurst P,
Farndale RW, Gachet C, Brandl R, Siess W. A 2-step mechanism
of arterial thrombus formation induced by human atherosclerotic
plaques. J Am Coll Cardiol 2010; 55: 1147–58.
21 van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HF, Con-
nolly TM, de Groot PG, Sixma JJ. Increased platelet deposition
on atherosclerotic coronary arteries. J Clin Invest 1994; 93: 615–
32.
22 Penz SM, Reininger AJ, Toth O, Deckmyn H, Brandl R, Siess
W. Glycoprotein Ibalpha inhibition and ADP receptor antago-
nists, but not aspirin, reduce platelet thrombus formation in
flowing blood exposed to atherosclerotic plaques. Thromb Hae-
most 2007; 97: 435–43.
23 Nergiz- €Unal R, Cosemans JM, Feijge MA, van der Meijden PE,
Storey RF, van Giezen JJ, oude Egbrink MG, Heemskerk JW,
Kuijpers MJ. Stabilizing role of platelet P2Y12 receptors in
shear-dependent thrombus formation on ruptured plaques. PLoS
ONE 2010; 5: e10130.
24 Schulz C, Konrad I, Sauer S, Orschiedt L, Koellnberger M, Lor-
enz R, Walter U, Massberg S. Effect of chronic treatment with
acetylsalicylic acid and clopidogrel on atheroprogression and ath-
erothrombosis in ApoE-deficient mice in vivo. Thromb Haemost
2008; 99: 190–5.
25 van Geffen JP, Kleinegris MC, Verdoold R, Baaten CC, Cose-
mans JM, Clemetson KJ, Ten Cate H, Roest M, de Laat B, He-
emskerk JW. Normal platelet activation profile in patients with
peripheral arterial disease on aspirin. Thromb Res 2015; 135:
513–20.
26 Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE. Vascular
wall-produced prostaglandin E2 exacerbates arterial thrombosis
and atherothrombosis through platelet EP3 receptors. J Exp
Med 2007; 204: 311–20.
27 Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O,
Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3
receptor for PGE2 with DG-041 decreases thrombosis without
impairing haemostatic competence. Cardiovasc Res 2014; 101:
482–91.
28 Schober LJ, Khandoga AL, Dwivedi S, Penz SM, Maruyama T,
Brandl R, Siess W. The role of PGE2 in human atherosclerotic
plaque on platelet EP3 and EP4 receptor activation and platelet
function in whole blood. J Thromb Thrombolysis 2011; 32: 158–
66.
29 Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B,
Mailhac A, Weng D, Shah PK, Badimon L. Characterization of
the relative thrombogenicity of atherosclerotic plaque compo-
nents: implications for consequences of plaque rupture. J Am
Coll Cardiol 1994; 23: 1562–9.
30 Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M,
Chesebro JH, Badimon L. Local inhibition of tissue factor
reduces the thrombogenicity of disrupted human atherosclerotic
plaques: effects of tissue factor pathway inhibitor on plaque
thrombogenicity under flow conditions. Circulation 1999; 99:
1780–7.
31 Kuijpers MJ, van der Meijden PE, Feijge MA, Mattheij NJ,
May F, Govers-Riemslag J, Meijers JC, Heemskerk JW, Renne
T, Cosemans JM. Factor XII regulates the pathological process
of thrombus formation on ruptured plaques. Arterioscler Thromb
Vasc Biol 2014; 34: 1674–80.
32 Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman
DT. Deficiency of tissue factor pathway inhibitor promotes
atherosclerosis and thrombosis in mice. Circulation 2001; 103:
3044–6.
33 van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag
JW, Cosemans JM, Kuijpers MJ, Spronk HM, Watson SP,
Renne T, Heemskerk JW. Dual role of collagen in factor XII-
dependent thrombus formation. Blood 2009; 114: 881–90.
34 van Montfoort ML, Kuijpers MJ, Knaup VL, Bhanot S, Monia
BP, Roelofs JJ, Heemskerk JW, Meijers JC. Factor XI regulates
pathological thrombus formation on acutely ruptured atheroscle-
rotic plaques. Arterioscler Thromb Vasc Biol 2014; 34: 1668–73.
35 Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthal-
er U, Stoll G, Dickneite G, Nieswandt B. Factor XIIa inhibitor
recombinant human albumin Infestin-4 abolishes occlusive arte-
rial thrombus formation without affecting bleeding. Circulation
2010; 121: 1510–7.
36 Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF,
White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renne
T, Gruber A, Gailani D. A role for factor XIIa-mediated factor
XI activation in thrombus formation in vivo. Blood 2010; 116:
3981–9.
37 B€uller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob
GE, Segers A, Verhamme P, Weitz JI; Investigators F-AT. Fac-
tor XI antisense oligonucleotide for prevention of venous throm-
bosis. N Engl J Med 2015; 372: 232–40.
38 Alame G, Mangin PH, Freund M, Riehl N, Magnenat S, Petitou
M, Hechler B, Gachet C. EP217609, a neutralisable dual-action
FIIa/FXa anticoagulant, with antithrombotic effects in arterial
thrombosis. Thromb Haemost 2015; 113: 385–95.
39 Cosemans JM, Mattheij NJ, Angelillo-Scherrer A, Heemskerk
JW. The effects of arterial flow on platelet activation, thrombus
growth and stabilization. Cardiovasc Res 2013; 99: 342–52.
40 Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasmino-
gen activator inhibitor-1 deficiency protects against atherosclerosis
progression in the mouse carotid artery. Blood 2000; 96: 4212–5.
41 Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L,
Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen
D, Carmeliet P. Lack of plasminogen activator inhibitor-1 pro-
motes growth and abnormal matrix remodeling of advanced ath-
erosclerotic plaques in apolipoprotein E-deficient mice.
Arterioscler Thromb Vasc Biol 2002; 22: 499–505.
42 Sch€afer K, Muller K, Hecke A, Mounier E, Goebel J, Loskutoff
DJ, Konstantinides S. Enhanced thrombosis in atherosclerosis-
prone mice is associated with increased arterial expression of
plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol
2003; 23: 2097–103.
43 Xian X, Ding Y, Zhang L, Wang Y, McNutt MA, Ross C, Hay-
den MR, Deng X, Liu G. Enhanced atherothrombotic formation
after oxidative injury by FeCl3 to the common carotid artery in
severe combined hyperlipidemic mice. Biochem Biophys Res Com-
mun 2009; 385: 563–9.
44 Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman
DT. Recombinant leptin promotes atherosclerosis and thrombo-
sis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc
Biol 2005; 25: e119–22.
45 van der Donckt C, van Herck JL, Schrijvers DM, Vanhoutte G,
Verhoye M, Blockx I, van der Linden A, Bauters D, Lijnen HR,
Sluimer JC, Roth L, van Hove CE, Fransen P, Knaapen MW,
Hervent AS, de Keulenaer GW, Bult H, Martinet W, Herman
AG, De Meyer GR. Elastin fragmentation in atherosclerotic
mice leads to intraplaque neovascularization, plaque rupture,
myocardial infarction, stroke, and sudden death. Eur Heart J
2014; 36: 1049–58.
46 Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage
expression of active MMP-9 induces acute plaque disruption in
apoE-deficient mice. J Clin Invest 2006; 116: 59–69.
47 von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM,
Havekes LM, van Berkel TJ, Biessen EA. Induction of athero-
sclerotic plaque rupture in apolipoprotein E/ mice after adeno-
virus-mediated transfer of p53. Circulation 2002; 105: 2064–70.
48 Welch CL, Sun Y, Arey BJ, Lemaitre V, Sharma N, Ishibashi
M, Sayers S, Li R, Gorelik A, Pleskac N, Collins-Fletcher K,
© 2015 International Society on Thrombosis and Haemostasis
Platelets and coagulation in atherothrombosis S279
Yasuda Y, Bromme D, D’Armiento JM, Ogletree ML, Tall AR.
Spontaneous atherothrombosis and medial degradation in
Apoe/, Npc1/ mice. Circulation 2007; 116: 2444–52.
49 Projahn D, Koenen RR. Platelets: key players in vascular
inflammation. J Leukoc Biol 2012; 92: 1167–75.
50 Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knar-
ren S, Kuziel WA, Weber C. Crucial role of the CCL2/CCR2
axis in neointimal hyperplasia after arterial injury in hyperlipi-
demic mice involves early monocyte recruitment and CCL2 pre-
sentation on platelets. Circ Res 2004; 95: 1125–33.
51 Burkhart JM, Gambaryan S, Watson SP, Jurk K, Walter U,
Sickmann A, Heemskerk JW, Zahedi RP. What can proteomics
tell us about platelets? Circ Res 2014; 114: 1204–19.
52 Schulz C, Massberg S. Platelets in atherosclerosis and thrombo-
sis. Handb Exp Pharmacol 2012; 210: 111–33.
53 Ramadan R, Dhawan SS, Syed H, Pohlel FK, Binongo JN,
Ghazzal ZB, Quyyumi AA. Effects of clopidogrel therapy on
oxidative stress, inflammation, vascular function, and progenitor
cells in stable coronary artery disease. J Cardiovasc Pharmacol
2014; 63: 369–74.
54 Blann AD, Kuzniatsova N, Lip GY. Vascular and platelet
responses to aspirin in patients with coronary artery disease. Eur
J Clin Invest 2013; 43: 91–9.
55 Borissoff JI, Otten JJ, Heeneman S, Leenders P, van Oerle R, Soe-
hnlein O, Loubele ST, Hamulyak K, Hackeng TM, Daemen MJ,
Degen JL, Weiler H, Esmon CT, van Ryn J, Biessen EA, Spronk
HM, ten Cate H. Genetic and pharmacological modifications of
thrombin formation in apolipoprotein e-deficient mice determine
atherosclerosis severity and atherothrombosis onset in a neutro-
phil-dependent manner. PLoS ONE 2013; 8: e55784.
56 Kalz J, ten Cate H, Spronk HM. Thrombin generation and
atherosclerosis. J Thromb Thrombolysis 2014; 37: 45–55.
57 Tilley RE, Pedersen B, Pawlinski R, Sato Y, Erlich JH, Shen Y,
Day S, Huang Y, Eitzman DT, Boisvert WA, Curtiss LK, Fay
WP, Mackman N. Atherosclerosis in mice is not affected by a
reduction in tissue factor expression. Arterioscler Thromb Vasc
Biol 2006; 26: 555–62.
58 Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP,
Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S,
Burton P, Stone G, Braunwald E; Investigators A-AT. Reduc-
tion of stent thrombosis in patients with acute coronary syn-
dromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J
Am Coll Cardiol 2013; 62: 286–90.
59 Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanan-
dan-Giri A, Rabquer BJ, Koch AE, Pennathur S, Davidson A,
Eitzman DT, Kaplan MJ. Type I interferons modulate vascular
function, repair, thrombosis, and plaque progression in murine
models of lupus and atherosclerosis. Arthritis Rheum 2012; 64:
2975–85.
60 Bampalis VG, Dwivedi S, Shai E, Brandl R, Varon D, Siess W.
Effect of 5-HT2A receptor antagonists on human platelet activa-
tion in blood exposed to physiologic stimuli and atherosclerotic
plaque. J Thromb Haemost 2011; 9: 2112–5.
61 Palazon CP, Alfon J, Gaffney P, Berrozpe M, Royo T, Badimon
L. Effects of reducing LDL and increasing HDL with gemfibrozil
in experimental coronary lesion development and thrombotic
risk. Atherosclerosis 1998; 136: 333–45.
62 Suades R, Padro T, Vilahur G, Badimon L. Circulating and plate-
let-derived microparticles in human blood enhance thrombosis on
atherosclerotic plaques. Thromb Haemost 2012; 108: 1208–19.
© 2015 International Society on Thrombosis and Haemostasis
S280 T. G. Mastenbroek et al
